Pharma ad spending soared to $4.5 billion in 2014, backing branded drugs in
levels not seen since the recession, with particular emphasis on
blockbusters--and wannabes. Drugmakers poured $3.4 million into advertising
spending on the top 10 drugs, which accounted for 75% of the total spent on all
advertising of pharmaceuticals, according to Nielsen data. The big push at the
top resulted in 5 drugs surpassing the $200 million mark in spending in 2014,
versus just two that crossed that threshold in 2013. Not surprisingly, household names ruled the list, with two erectile
dysfunction treatments in the top 10.
Eli Lilly's ($LLY) Cialis took over as the No. 1 spender while its chief competitor, Pfizer's ($PFE) Viagra, remained close by at No. 4. AbbVie's ($ABBV) Humira, which was the top spender in 2013, was one of the few that saw a decrease
in spending, albeit minor, resulting in a drop to No. 5 as other brands loaded
up on paid media.
New to the top 10 this year were Sunovion Pharmaceutical's Latuda at No. 6 and Pfizer's Chantix at No. 10. Latuda pushed a new
indication, while Pfizer continued an aggressive marketing march for its
anti-smoking pill, amid and despite controversy.
Dropping out of the top 10 were AstraZeneca's ($AZN) Crestor, and Bayer and Johnson & Johnson's ($JNJ) Xarelto. Crestor is up against its patent loss in the U.S. next year, while
Xarelto faced a rash of mass tort lawsuits with law firms spending
millions--$22.5 million from July through December last year--to lure clients.
The Nielsen data did not include Internet advertising, but eMarketer predicted that pharmaceutical and healthcare companies would spend $1.4 billion on
paid digital media in 2014, with $373 million of that spent on mobile
marketing.
Kantar Media, which also tracks paid media ad spending, recently released
its top 5 drug spenders, and its results do include digital advertising--which
it totaled at $246 million in 2014, down 4% from 2013.
Nielsen and Kantar both totted up the same top 5 ad spenders, just in
slightly different order. See below for Nielsen's top 10; Kantar ranked the top
5 in the following order: Cialis ($272 million), Humira ($259 million), Lyrica
($246 million), Viagra ($232 million) and Eliquis ($221 million).
(Πατήστε στο όνομα κάθε εταιρίας για να δείτε αναλυτικές πληροφορίες)
Κατάταξη
|
Brand
|
1
|
|
2
|
|
3
|
|
4
|
|
5
|
|
6
|
|
7
|
|
8
|
|
9
|
|
10
|
Φαρμακευτικό Μάρκετινγκ: Θεωρία, Πρακτική, Δεοντολογία
Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…
The
ultimate guide for Pharma Marketing Champions
Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…